MedTrace Logo

Paracetamol for Cancer Pain

NCT01313247 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-03-11

No results posted yet for this study

Summary

Randomised, double-blind placebo controlled cross-over trial

Main goal:

Optimize the medical pain treatment for patients with advanced cancer disease

Study goal:

Measure paracetamol's additional analgesic effect in a situation where the patient is concomitantly treated with oral opioids eqv. morphine \> 100 mg/d.

Conditions

Interventions

DRUG

paracetamol

1000 mg 4 times daily

DRUG

placebo tablets

Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol

Sponsors & Collaborators

  • Haraldsplass Deaconess Hospital

    lead OTHER

Principal Investigators

  • Jan Henrik Rosland, MD, PhD · Haraldsplass Deaconess Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01313247 on ClinicalTrials.gov